Multiple Myeloma
Dr. James R. Berenson's private practice in West Hollywood specializes in the treatment of multiple myeloma & its related diseases.
Improving Lives
Individualized therapeutic plans emphasize effective treatments that benefit each patient's quality of life.
Top Research
Dr. James R. Berenson’s team of laboratory and clinical researchers have led to many of the major breakthroughs for treating and improving the lives of patients with myeloma.
Skilled Team
BCC has a team with extensive training and clinical experience.
Dr. James Berenson
President & Medical Director, Berenson Cancer Center
Dr. James R. Berenson has his private practice in West Hollywood, California and has specialized in the treatment of patients with multiple myeloma, MGUS, amyloidosis, Waldenstrom’s macroglobulinemia and metastatic bone disease. He has been conducting research related to these disorders both in the basic and clinical areas for more than 30 years. Dr. Berenson has been involved in many of the major breakthroughs that have brought new treatments to patients with these diseases resulting in both an improvement in the length and quality of their lives.
Dr. Berenson serves as a member of the National Institutes of Health – Center for Scientific Review, Clinical Oncology Study Section. He is a member of the Scientific Boards of the Multiple Myeloma Research Foundation, the International Myeloma Foundation and the International Waldenstrom’s Macroglobulinemia Foundation. He serves on both the Foundation and the Scientific Boards of the Leukemia, Lymphoma and Myeloma Society. He also works with many other groups known for their work in multiple myeloma and bone metastases.
President & Medical Director, Berenson Cancer Center
President & CEO, Institute for Myeloma & Bone Cancer Research (IMBCR)
Founder & President, ONCOtherapeutics
Founder & Principal, ONCOtracker
A History of Innovation and Insight
After receiving a Bachelor of Science with Distinction from Stanford University, Dr. Berenson earned his Doctorate in Medicine from the University of California at San Diego. He completed his internship and residency in internal medicine at the University of Utah Medical Center and fellowships in hematology/oncology at the University of California at Los Angeles (UCLA). Dr. Berenson is certified by the American Board of Internal Medicine in both internal medicine and medical oncology.
He has served as the Director of Multiple Myeloma & Bone Metastasis Programs in the Department of Medicine at Cedars-Sinai Medical Center. Dr. Berenson was Professor in Residence in the Division of Hematology/Oncology at the UCLA School of Medicine and served as co-chair of its Hematologic Malignancies Program.
Dr. Berenson has authored and co-authored numerous books, articles, and abstracts in journals including Blood, Cancer, Cancer Research, Journal of Clinical Investigation, Journal of Clinical Oncology, New England Journal of Medicine, and Science. In addition to his research interests in myeloma and metastatic bone disease, he also studies antibodies, T-cell receptors, cytokines, cancer genes, viruses and blood vessel development.
Also, he has conducted numerous clinical trials related to the treatment of multiple myeloma and metastatic bone disease. Because he is internationally known for his expertise and accomplishments in these areas, Dr. Berenson has also been asked to give numerous lectures and organize many meetings both nationally and internationally.
Dr. Berenson was born and raised in Portland, Oregon. He has been married to Debra for more than 40 years. They have two daughters, Ariana Berenson, Shira Feinstein, son-in-law Dr Aaron Feinstein, and grandsons Jacob and Noah.
Recent Articles
Cancer Patients Join Oncologist Who Releases Results of COVID-19 Vaccine/Cancer Study
On the heels of his study, Dr. James Berenson an oncologist specializing in multiple myeloma —announced his latest findings and with his cancer patients, shared their challenging experiences during this...
IMBCR & Emory University’s Big Discovery!!!
Multiple myeloma (MM) patients are at higher risk for severe COVID-19. Their mRNA vaccination response against...
James R. Berenson, MD, Inc. Announces Rebranding and Changes Organization Name to Berenson Cancer Center
New name, logo, and business unit alignment introduced as part of an extensive rebranding initiative LOS ANGELES, Nov....
What is Multiple Myeloma?
Survival and treatments are improving for this type of blood cancer You don't expect to break a rib while doing light...
Combined TRAF6 Targeting and Proteasome Blockade has Anti-tumor and Anti-bone Resorptive Effects
Abstract Tumor necrosis factor receptor-associated factor 6 (TRAF6) has been implicated in polyubiquitin-mediated...